1 All exons of ASTN1 (NM_004319.1) were sequenced via exome sequencing (in 306 unrelated ASD probands of European ancestry) or whole genome sequencing (in 32 unrelated ASD probands of European ancestry) and all rare (<1% in 1000 genomes) missense changes were recorded. Exome and WGS calls were confirmed using Sanger sequencing in the proband. 2 The nucleotide change from the reference sequence and the cDNA position of this change are recorded in this column. 3 These three columns denote the number of ASD cases with each genotype: homozygous for the reference allele (AA), heterozygous (AB) and homozygous for the minor allele (BB). 4 The minor allele frequency (MAF) was calculated for our ASD case cohort and recorded as stated in the NCBI dbSNP database (build 137). 5 The minor allele frequency (MAF) of these variants was determined from 4,300 individuals of European ancestry who were exome sequenced as part of the NIH National Heart, Lung and
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Figure S1. Exonic CNVs reported at the ASTN2/TRIM32 locus by previous studies.
Blue and red bars represent duplications and deletions respectively. Dashed purple lines intersect CNVs that overlap exons shared by multiple ASTN2 isoforms and green lines intersect those affecting only the long isoform. Dashed vertical blue line intersects CNVs that overlap an exon of TRIM32. Genomic locations and coordinates are based on hg18 (NCBI36). Information about genes and transcript isoforms was obtained from the RefSeq database. The three transcript isoforms of ASTN2 possessing different number of exons are depicted including the long isoform (NM_014010) and two shorter isoforms (NM_198186 and NM_001184735). The three other shorter isoforms of the gene (NM_198187, NM_198188 and NM_001184734) have the same number and location of exons as NM_198186 but differ slightly in the length of their first and terminal exons and UTRs. CNVs presented in this figure are from the following genome-wide microarray scans of different neurodevelopmental disorders: Vrijenhoek et al., (1) . The significant enrichments of exonic deletions affecting multiple ASTN2 isoforms in NDD cases vs, controls (p = 0.009) and in male NDD cases vs. male controls (p = 0.015) are still observed if these cases are removed from the CNV analyses.
Figure S2. Exonic gains at the ASTN2/TRIM32 locus in clinical and control cohorts.
Exonic duplications identified in 12 / 89,985 cases and 5 / 44,085 controls are depicted. All described duplication CNVs in the cases, except for the one in male patient 48, involve only the 5' portion of the longest isoform of ASTN2. These duplications were not found to be significantly enriched in cases vs. controls and their etiological contribution is unclear. Filled blue bars represent duplications detected in individuals with NDD phenotypes. Empty blue bars denote duplications in cases without known NDD traits from available clinical information and in controls. Numbers adjacent to the bars are the randomized sample ids of individuals with the duplications and correlate with information in Table 2 , Table S1 and Table S3 . Gender information was not available for the control individual (CU24) marked with * at the bottom of the figure. Dashed purple lines intersect duplications that overlap exons shared by multiple ASTN2 isoforms and green lines intersect duplications affecting only the long isoform. Dashed vertical black line intersects duplications that overlap an exon of TRIM32. Genomic locations and coordinates are based on hg18 (NCBI36). Information about genes and transcript isoforms was obtained from the RefSeq database.
Figure S3. Functional impact of ASTN2 deletions on gene expression in lymphoblasts.
A) Pedigrees of the two families used for ASTN2 expression analysis. Arrows indicate the index probands of the pedigrees (denoted as patients 14 and 22 in this study). Individuals with black shading have an ASD diagnosis while the person represented by gray shading reported depression and anxiety issues. B) Relative ASTN2 expression in lymphoblast cell lines from the six individuals (3 males and 3 females) with ASTN2 deletions in the two pedigrees were compared to lymphoblast cell-lines from 9 individuals (5 males and 4 females) with two copies of ASTN2. The latter group included the three individuals without deletions in the two pedigrees as well as six additional samples with two copies of ASTN2. The lymphoblast cell lines were cultured as previously described.(8) Total RNA was extracted using Qiagen RNeasy mini kit with DNase I treatment (QIAGEN, Valencia, CA, USA). cDNA synthesis and qRT-PCR were performed as described in the main Methods. The expression was measured using two different primer pairs which detected all ASTN2 isoforms (Table S10 ). ASTN2 expression was normalized using GAPDH (dCt) and the fold change was calculated using the ΔΔCt method. Student's T-test was used to assess the expression difference between the two sample groups for statistical significance.
Figure S4. Conservation analysis of untranslated regions (UTRs) of ASTN2 and TRIM32
exons. The conservation was determined using average PhyloP scores calculated from nucleotide alignments between 46 vertebrate species including 23 placental mammals and eight primate species. Locations of the UTRs of different ASTN2 transcript isoforms are labeled using the exon numbering in Figure 3A . Figure S5 . Amino acid alignment and protein conservation analysis of ASTN2. Eight protein sequences from 1:1 orthologs of human ASTN2 (ENSP00000354504): macaque (ENSMMUP00000039777), chimpanzee (ENSPTRP00000036394), horse (ENSECAP00000003457), mouse (ENSMUSP00000065786), dog (ENSCAFP00000005232), chicken (ENSGALP00000011381) and clawed frog (ENSXETP00000047008), were downloaded from Ensembl. "*" indicates identical residues in all sequences, ":" and "." denote conserved substitutions or semi-conserved substitutions respectively.
Figure S6. Quantification of residue conservation profile of ASTN2 (ENSP00000354504).
Conservation score was calculated based on alignment in Figure S5 using the Scorecons server.(9) The known protein domains and features of ASTN2 are shown in the schematic illustration above the chart. The signal peptide (SP) is marked red, trans-membrane (TM) domains are marked light blue, EGF/laminin superfamily (EGF) domains are marked light green, the MACPF domain is marked blue and the fibronectin domain type 3 (FN III) is marked dark green. The critical region with enrichment of exonic deletions affecting multiple ASTN2 isoforms in NDD cases from Figure 1 is shown in grey. Vertical red dashed lines correspond to the exon boundaries. Figure S7 . Functional enrichment maps of genes co-expressed with ASTN2. These maps depict the results of the gene set enrichment analysis of genes co-expressed with ASTN2 in the frontal cortex (A) and the cerebellar cortex (B). Using the brain expression data from Brainspan,(10) the Pearson correlation coefficients were calculated between the expression levels of genes in the dataset and ASTN2 in the CBC and FC regions. The top 500 most correlated genes for the two regions (Table S7 ) were used as inputs for the gene set enrichment analysis implementing manually curated gene ontology (GO) (org.Hs.eg.db, version 2.8.0) and pathways (downloaded from NCI, KEGG and Reactome websites) as previously described. (11, 12) Independently for the FC and the CBC, all expressed genes in each region were used as a background gene set and the statistical significance and false-discovery rate were calculated using the Fisher exact test and the Benjamini-Hochberg procedure respectively. The Cytoscape network software v.2.8.3 and the plugin Enrichment Map (version 1.2) were used to build the network. The functional enrichment maps were constructed using a false discovery rate cutoff of 20% and the gene-set clusters were manually identified and annotated (blue ovals) The node size is proportional to the gene-set size and the color corresponds to the odds ratio of enrichment (found in Table S7 ). Table S9 ). "Cases only" represent those microarray platforms utilized solely for CNV analysis of clinical samples (Cases in Table S9 ), "Controls only" represent microarray platforms from which CNV data was obtained for control individuals (Controls in Table S9 ) and "Cases/Controls" indicate microarray platforms from which CNV information was obtained for both case and control datasets (Cases, controls in Table S9 ). The plots reveal that the Control CNV dataset is generated from microarrays of resolutions significantly greater than or equal to those used to generate the Case CNV dataset. All exons of ASTN2 (NM_014010.4) were sequenced via exome sequencing (in 159 unrelated ASD probands of European ancestry) or whole genome sequencing (in 23 unrelated ASD probands of European ancestry) and all rare (<1% in 1000 genomes) missense changes were recorded. Exome and WGS calls were confirmed using Sanger sequencing in the proband. 2 The nucleotide change from the reference sequence and the cDNA position of this change are recorded in this column. 3 These three columns denote the number of ASD cases with each genotype: homozygous for the reference allele (AA), heterozygous (AB) and homozygous for the minor allele (BB). 4 The minor allele frequency (MAF) was calculated for our ASD case cohort and recorded as stated in the NCBI dbSNP database (build 137). 5 The minor allele frequency (MAF) of these variants was determined from 4,300 individuals of European ancestry who were exome sequenced as part of the NIH National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). 6 Inheritance was determined via Sanger sequencing of both parents for all variants previously confirmed in probands. 7 The effects of the resulting amino acid changes on protein function were predicted using SIFT Human Protein (http://sift.jcvi.org/) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/). Table S6 : TRIM32 missense sequence variants in 182 Canadian ASD cases 1 1 All exons of TRIM32 (NM_012210.3) were sequenced via exome sequencing (in 159 unrelated ASD probands of European ancestry) or whole genome sequencing (in 23 unrelated ASD probands of European ancestry) and all rare (<1% in 1000 genomes) missense changes were recorded. Exome and WGS calls were confirmed using Sanger sequencing in the proband. 2 The nucleotide change from the reference sequence and the cDNA position of this change are recorded in this column. 3 These three columns denote the number of ASD cases with each genotype: homozygous for the reference allele (AA), heterozygous (AB) and homozygous for the minor allele (BB). 4 The minor allele frequency (MAF) was calculated for our ASD case cohort and recorded as stated in the NCBI dbSNP database (build 137). 5 The minor allele frequency (MAF) of these variants was determined from 4,300 individuals of European ancestry who were exome sequenced as part of the NIH National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). 6 Inheritance was determined via Sanger sequencing of both parents for all variants previously confirmed in probands. 7 The effects of the resulting amino acid changes on protein function were predicted using SIFT Human Protein (http://sift.jcvi.org/) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/). 
